Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy

Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Key clinical point: Renal cell carcinoma patients with brain-only metastases may experience durable long-term survival following cytoreductive nephrectomy.

Major finding: Two-year survival was 52% and 14%, respectively, for patients with brain-only metastases who did and did not undergo the procedure.

Study details: A retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) Program data including 6,403 patients with metastatic RCC and complete data on sites of metastasis.

Disclosures: Dr. Bratslavsky and coauthors listed no disclosures related to their research.

Read the article here.

Citation:

Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021.